Drug Inspectors Mandated to Ramp Up Inspections Amid Compliance Lapses

Madhubani, Bihar – In a bid to strengthen regulatory oversight in the pharmaceutical sector, authorities in Madhubani district have reissued strict guidelines requiring drug inspectors to conduct a minimum of 20 routine inspections and 5 joint surprise raids every month. The directive comes in response to observed lapses in enforcement, including delays in drug licensing and recurring violations at sales outlets.

According to local health department officials, the renewed instructions aim to address inconsistencies uncovered during a recent audit of the Online Drug Licensing System (ONDLS). Inspectors have been reminded that failure to meet these targets could lead to further scrutiny, as some personnel have reportedly fallen short in their duties.

Key Enforcement Measures Outlined

The guidelines, which were originally circulated but now reiterated for emphasis, include several critical operational requirements:
  • Monthly Inspection Quota: Each drug inspector must perform at least 20 standard inspections of pharmaceutical establishments and 5 collaborative surprise checks or raids, involving coordination with other regulatory teams.
  • Action on Repeat Violations: If similar errors—such as improper storage, labeling issues, or unlicensed sales—are detected multiple times at the same outlet, inspectors are empowered to initiate immediate corrective actions. A mandatory report of these steps must be forwarded to the Deputy Drug Controller for oversight.
  • Expedited Licensing Process: Reviewing officers are directed to fast-track applications for new drug licenses, which have previously been stalled for 20-25 days. This bottleneck has delayed license issuances and hampered business operations for legitimate vendors.
  • Detailed Reporting Standards: All inspection reports must now include comprehensive details, such as the full name and address of the pharmaceutical sales establishment, along with the proprietor’s email address (where available), to enhance traceability and follow-up.
These measures are part of a broader push to ensure public safety and compliance with national drug control standards under the Drugs and Cosmetics Act. Officials noted that the pharmaceutical trade in Madhubani, a key district in Bihar’s cosmetics and herbal medicine hub, has seen a surge in outlets, necessitating more vigilant monitoring.
While specific names of issuing officials were not disclosed in the directive, sources within the district’s drug control wing emphasized that the guidelines stem from a high-level review of enforcement data. “The goal is not just to meet numbers but to prevent risks to consumers from substandard or counterfeit drugs,” one anonymous regulator stated.
As Bihar continues to grapple with counterfeit drug challenges, this initiative in Madhubani could serve as a model for other districts. Health experts predict that consistent implementation could reduce violation rates by up to 30% within the next quarter.

Related Posts

Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

New Delhi: The entry of semaglutide generics in India is ‘stimulating’ market growth and providing a favourable push to Eli Lilly’s blockbuster brand Mounjaro (tirzepatide), said Patrik Jonsson, Executive Vice…

Pak-made illegal cosmetics recovered from Itwari shop

Nagpur: Maharashtra Food and Drug Administration (FDA), Nagpur Division, raided a cosmetics firm in Itwari market and seized Pakistan-origin beauty products suspected to have harmful mercury and steroids last week. The…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

Pak-made illegal cosmetics recovered from Itwari shop

Pak-made illegal cosmetics recovered from Itwari shop

Licences of 20 medical stores suspended after inspections

Licences of 20 medical stores suspended after inspections

Bain Capital sells nearly 1 pc stake in Emcure Pharma for Rs 289 crore

Bain Capital sells nearly 1 pc  stake in Emcure Pharma for Rs 289 crore

Sun Pharma to acquire U.S. firm Organon in $11.75 billion deal

Sun Pharma to acquire U.S. firm Organon in $11.75 billion deal

HP accounts for 47 inferior drugs in March alert

HP accounts for 47 inferior drugs in March alert